

Antiviral Drugs Market Research Report by Drug Type (Branded Drugs and Generic Drugs), by Therapeutics (HIV/Aids Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia), by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19

<https://marketpublishers.com/r/AA98D06CF935EN.html>

Date: February 2021

Pages: 182

Price: US\$ 3,949.00 (Single User License)

ID: AA98D06CF935EN

Abstracts

Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Antiviral Drugs Market is expected to grow from USD 46,912.64 Million in 2020 to USD 61,347.42 Million by the end of 2025.
2. The Global Antiviral Drugs Market is expected to grow from EUR 41,133.89 Million in 2020 to EUR 53,790.58 Million by the end of 2025.
3. The Global Antiviral Drugs Market is expected to grow from GBP 36,568.12 Million in 2020 to GBP 47,819.95 Million by the end of 2025.
4. The Global Antiviral Drugs Market is expected to grow from JPY 5,006,767.58 Million in 2020 to JPY 6,547,324.96 Million by the end of 2025.
5. The Global Antiviral Drugs Market is expected to grow from AUD 68,123.39 Million in 2020 to AUD 89,084.62 Million by the end of 2025.

Market Segmentation & Coverage:

This research report categorizes the Antiviral Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug Type, the Antiviral Drugs Market studied across Branded Drugs and Generic Drugs.

Based on Therapeutics, the Antiviral Drugs Market studied across HIV/Aids Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia.

Based on End Use, the Antiviral Drugs Market studied across Ambulatory Surgical Centres, Clinics, and Hospitals.

Based on Geography, the Antiviral Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:

The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Antiviral Drugs Market including Abacus Bioscience, Abbott Healthcare, AbbVie Inc., Antiva Biosciences, Inc., AstraZeneca plc, Aurobindo Pharma, Bristol-Myers-Squibb, Chimerix, Cipla, Dr. Reddy, Dr. Reddy's Laboratories Ltd., ENYO Pharma SA, F. Hoffmann-La Roche AG, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co., Mymetics, ReViral, Roche Holding AG, and Schering-Plough.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, so far and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

360iResearch FPNV Positioning Matrix:

The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Antiviral Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

360iResearch Competitive Strategic Window:

The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:

1. **Market Penetration:** Provides comprehensive information on the market offered by the key players
2. **Market Development:** Provides in-depth information about lucrative emerging markets and analyzes the markets
3. **Market Diversification:** Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. **Competitive Assessment & Intelligence:** Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. **Product Development & Innovation:** Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Antiviral Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antiviral Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antiviral Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Antiviral Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Antiviral Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global

Antiviral Drugs Market?

Contents

1. PREFACE

- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Stakeholders

2. RESEARCH METHODOLOGY

- 2.1. Research Process
 - 2.1.1. Define: Research Objective
 - 2.1.2. Determine: Research Design
 - 2.1.3. Prepare: Research Instrument
 - 2.1.4. Collect: Data Source
 - 2.1.5. Analyze: Data Interpretation
 - 2.1.6. Formulate: Data Verification
 - 2.1.7. Publish: Research Report
 - 2.1.8. Repeat: Report Update
- 2.2. Research Execution
 - 2.2.1. Initiation: Research Process
 - 2.2.2. Planning: Develop Research Plan
 - 2.2.3. Execution: Conduct Research
 - 2.2.4. Verification: Finding & Analysis
 - 2.2.5. Publication: Research Report
- 2.3. Research Outcome

3. EXECUTIVE SUMMARY

- 3.1. Introduction
- 3.2. Market Outlook
- 3.3. Drug Type Outlook
- 3.4. End Use Outlook
- 3.5. Therapeutics Outlook
- 3.6. Geography Outlook

3.7. Competitor Outlook

4. MARKET OVERVIEW

4.1. Introduction

4.2. Cumulative Impact of COVID-19

5. MARKET INSIGHTS

5.1. Market Dynamics

5.1.1. Drivers

5.1.1.1. Growing occurrence of viral diseases such as HIV, hepatitis, and influenza

5.1.1.2. Rising government and private sector expenditure in the development of antiviral drugs

5.1.1.3. Extensive geriatric population coupled with healthcare awareness among consumers

5.1.2. Restraints

5.1.2.1. Expiry of patents and generic erosion

5.1.2.2. Capital intensive antiviral drug treatment

5.1.3. Opportunities

5.1.3.1. Burgeoning research and development in the production of vaccines for numerous viral infections and diseases

5.1.3.2. Extensive formulations to develop HIV vaccines

5.1.4. Challenges

5.1.4.1. Prevalence of alternative therapy such as homeopathy

5.2. Porters Five Forces Analysis

5.2.1. Threat of New Entrants

5.2.2. Threat of Substitutes

5.2.3. Bargaining Power of Customers

5.2.4. Bargaining Power of Suppliers

5.2.5. Industry Rivalry

6. GLOBAL ANTIVIRAL DRUGS MARKET, BY DRUG TYPE

6.1. Introduction

6.2. Branded Drugs

6.3. Generic Drugs

7. GLOBAL ANTIVIRAL DRUGS MARKET, BY THERAPEUTICS

- 7.1. Introduction
- 7.2. HIV/Aids Therapeutics
- 7.3. Hepatitis (B & C) Therapeutics
- 7.4. Herpes Therapeutics
- 7.5. Influenza Therapeutics
- 7.6. Pneumonia

8. GLOBAL ANTIVIRAL DRUGS MARKET, BY END USE

- 8.1. Introduction
- 8.2. Ambulatory Surgical Centres
- 8.3. Clinics
- 8.4. Hospitals

9. AMERICAS ANTIVIRAL DRUGS MARKET

- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States

10. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET

- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. South Korea
- 10.10. Thailand

11. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET

- 11.1. Introduction
- 11.2. France
- 11.3. Germany
- 11.4. Italy
- 11.5. Netherlands
- 11.6. Qatar
- 11.7. Russia
- 11.8. Saudi Arabia
- 11.9. South Africa
- 11.10. Spain
- 11.11. United Arab Emirates
- 11.12. United Kingdom

12. COMPETITIVE LANDSCAPE

- 12.1. FPNV Positioning Matrix
 - 12.1.1. Quadrants
 - 12.1.2. Business Strategy
 - 12.1.3. Product Satisfaction
- 12.2. Market Ranking Analysis
- 12.3. Market Share Analysis
- 12.4. Competitor SWOT Analysis
- 12.5. Competitive Scenario
 - 12.5.1. Merger & Acquisition
 - 12.5.2. Agreement, Collaboration, & Partnership
 - 12.5.3. New Product Launch & Enhancement
 - 12.5.4. Investment & Funding
 - 12.5.5. Award, Recognition, & Expansion

13. COMPANY USABILITY PROFILES

- 13.1. Abacus Bioscience
- 13.2. Abbott Healthcare
- 13.3. AbbVie Inc.
- 13.4. Antiva Biosciences, Inc.
- 13.5. AstraZeneca plc
- 13.6. Aurobindo Pharma
- 13.7. Bristol-Myers-Squibb
- 13.8. Chimerix

- 13.9. Cipla
- 13.10. Dr. Reddy
- 13.11. Dr. Reddy's Laboratories Ltd.
- 13.12. ENYO Pharma SA
- 13.13. F. Hoffmann-La Roche AG
- 13.14. Gilead Sciences
- 13.15. GlaxoSmithKline
- 13.16. Johnson & Johnson
- 13.17. Merck & Co.
- 13.18. Mymetics
- 13.19. ReViral
- 13.20. Roche Holding AG
- 13.21. Schering-Plough

14. APPENDIX

- 14.1. Discussion Guide
- 14.2. License & Pricing

List Of Tables

LIST OF TABLES

TABLE 1. CURRENCY CONVERSION RATES

TABLE 2. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, BY

GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, BY

GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS,

2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV/AIDS

THERAPEUTICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C)

THERAPEUTICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES

THERAPEUTICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 11. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA

THERAPEUTICS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 12. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, BY

GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 13. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY

SURGICAL CENTRES, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD

MILLION)

TABLE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, BY

GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 16. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, BY

GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 17. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY,

2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 18. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE,

2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 19. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 20. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 21. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 22. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 23. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 24. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 25. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 26. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 27. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 28. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 29. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 30. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 31. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 32. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 33. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 34. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 35. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 36. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 37. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

- TABLE 38. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 39. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 40. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 41. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 42. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 43. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 44. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 45. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 46. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 47. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 48. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 49. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 50. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 51. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 52. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 53. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 54. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 55. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 56. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
- TABLE 57. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS,

2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 58. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 59. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 60. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 61. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 62. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 63. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 64. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 65. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 66. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 67. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 68. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 69. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 70. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 71. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 72. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 73. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 74. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 75. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 76. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 77. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 78. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 79. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 80. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 81. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY END USE,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 82. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY
THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 83. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 84. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 85. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 86. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 87. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 88. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 89. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 90. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY END USE,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 91. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 92. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 93. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY END USE,
2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 94. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY
THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 95. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025
(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 96. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025

(USD/EUR/GBP/JPY/AUD MILLION)

TABLE 97. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 98. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 99. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 100. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 101. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 102. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 103. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)

TABLE 104. GLOBAL ANTIVIRAL DRUGS MARKET: SCORES

TABLE 105. GLOBAL ANTIVIRAL DRUGS MARKET: BUSINESS STRATEGY

TABLE 106. GLOBAL ANTIVIRAL DRUGS MARKET: PRODUCT SATISFACTION

TABLE 107. GLOBAL ANTIVIRAL DRUGS MARKET: RANKING

TABLE 108. GLOBAL ANTIVIRAL DRUGS MARKET: MERGER & ACQUISITION

TABLE 109. GLOBAL ANTIVIRAL DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP

TABLE 110. GLOBAL ANTIVIRAL DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT

TABLE 111. GLOBAL ANTIVIRAL DRUGS MARKET: INVESTMENT & FUNDING

TABLE 112. GLOBAL ANTIVIRAL DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION

TABLE 113. GLOBAL ANTIVIRAL DRUGS MARKET: LICENSE & PRICING

List Of Figures

LIST OF FIGURES

FIGURE 1. GLOBAL ANTIVIRAL DRUGS MARKET: RESEARCH PROCESS

FIGURE 2. GLOBAL ANTIVIRAL DRUGS MARKET: RESEARCH EXECUTION

FIGURE 3. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)

FIGURE 4. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2020 (USD MILLION)

FIGURE 5. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2020 (USD MILLION)

FIGURE 6. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2020 (USD MILLION)

FIGURE 7. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)

FIGURE 8. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, 2018-2025 (USD MILLION)

FIGURE 9. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 10. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 11. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 12. GLOBAL ANTIVIRAL DRUGS MARKET: MARKET DYNAMICS

FIGURE 13. GLOBAL ANTIVIRAL DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS

FIGURE 14. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2025 (%)

FIGURE 15. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2020 VS 2025 (USD MILLION)

FIGURE 16. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY DRUG TYPE, 2025

FIGURE 17. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY BRANDED DRUGS, 2020 VS 2025 (USD MILLION)

FIGURE 18. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY GENERIC DRUGS, 2020 VS 2025 (USD MILLION)

FIGURE 19. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2020 VS 2025 (%)

FIGURE 20. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2020

VS 2025 (USD MILLION)

FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY THERAPEUTICS, 2025

FIGURE 22. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HIV/AIDS THERAPEUTICS, 2020 VS 2025 (USD MILLION)

FIGURE 23. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HEPATITIS (B & C) THERAPEUTICS, 2020 VS 2025 (USD MILLION)

FIGURE 24. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HERPES THERAPEUTICS, 2020 VS 2025 (USD MILLION)

FIGURE 25. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY INFLUENZA THERAPEUTICS, 2020 VS 2025 (USD MILLION)

FIGURE 26. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY PNEUMONIA, 2020 VS 2025 (USD MILLION)

FIGURE 27. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2020 VS 2025 (%)

FIGURE 28. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2020 VS 2025 (USD MILLION)

FIGURE 29. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY END USE, 2025

FIGURE 30. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTRES, 2020 VS 2025 (USD MILLION)

FIGURE 31. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY CLINICS, 2020 VS 2025 (USD MILLION)

FIGURE 32. GLOBAL ANTIVIRAL DRUGS MARKET SIZE, BY HOSPITALS, 2020 VS 2025 (USD MILLION)

FIGURE 33. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 34. AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 36. ARGENTINA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 37. BRAZIL ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 38. CANADA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 39. MEXICO ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 40. UNITED STATES ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 41. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 42. ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 44. AUSTRALIA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 45. CHINA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 46. INDIA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 47. INDONESIA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 48. JAPAN ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 49. MALAYSIA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 50. PHILIPPINES ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 51. SOUTH KOREA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 52. THAILAND ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 53. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)

FIGURE 54. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)

FIGURE 55. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2025

FIGURE 56. FRANCE ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 57. GERMANY ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 58. ITALY ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 59. NETHERLANDS ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY,

2018-2025 (USD MILLION)

FIGURE 60. QATAR ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY,
2018-2025 (USD MILLION)

FIGURE 61. RUSSIA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY,
2018-2025 (USD MILLION)

FIGURE 62. SAUDI ARABIA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY,
2018-2025 (USD MILLION)

FIGURE 63. SOUTH AFRICA ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY,
2018-2025 (USD MILLION)

FIGURE 64. SPAIN ANTIVIRAL DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025
(USD MILLION)

FIGURE 65. UNITED ARAB EMIRATES ANTIVIRAL DRUGS MARKET SIZE, BY
GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 66. UNITED KINGDOM ANTIVIRAL DRUGS MARKET SIZE, BY
GEOGRAPHY, 2018-2025 (USD MILLION)

FIGURE 67. GLOBAL ANTIVIRAL DRUGS MARKET: 360IRESEARCH FPNV
POSITIONING MATRIX

FIGURE 68. GLOBAL ANTIVIRAL DRUGS MARKET: 360IRESEARCH MARKET
SHARE ANALYSIS

FIGURE 69. GLOBAL ANTIVIRAL DRUGS MARKET: COMPETITOR SWOT
ANALYSIS

FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL ANTIVIRAL DRUGS
MARKET, BY TYPE

I would like to order

Product name: Antiviral Drugs Market Research Report by Drug Type (Branded Drugs and Generic Drugs), by Therapeutics (HIV/Aids Therapeutics, Hepatitis (B & C) Therapeutics, Herpes Therapeutics, Influenza Therapeutics, and Pneumonia), by End Use - Global Forecast to 2025 - Cumulative Impact of COVID-19

Product link: <https://marketpublishers.com/r/AA98D06CF935EN.html>

Price: US\$ 3,949.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AA98D06CF935EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970